9:53 AM
 | 
Sep 26, 2018
 |  BC Extra  |  Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) added $3.45 (35%) to $13.35 on Wednesday after reporting that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans to start Phase III testing of the candidate next year.

Aldeyra shares touched an all-time high of $16.70 on Wednesday, almost four times their value in September 2017 before the company issued data from a Phase IIa trial of...

Read the full 348 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >